Expensive, potentially curative gene therapies force a basic governance question: who decides who gets them? The answer matters because decisions shape clinical outcomes, public budgets, and social perceptions of fairness. High prices reflect concentrated development costs, small eligible populations, and regulatory incentives such as the Orphan Drug Act in the United States, creating tension between innovation and equitable access.
Ethical and economic stakes
From an ethical perspective the debate centers on justice and beneficence: treating rare, severe conditions with transformative therapies can avert lifelong disability and high downstream costs, but paying for a one-time treatment at prices like those established for gene therapies risks crowding out other health services. The Institute for Clinical and Economic Review under Steven D. Pearson has emphasized the role of independent evaluation of value to inform fair pricing and coverage decisions, while health economists such as Anupam B. Jena at Harvard Medical School have written about aligning payment with long-term benefits to avoid perverse incentives. Policy causes include high fixed research and development costs, regulatory pathways that reward rarity, and market exclusivities that enable manufacturers to set steep prices; corporate pricing decisions are visible in cases such as Novartis pricing its spinal muscular atrophy therapy at approximately 2.1 million dollars.
Models for decision-making and governance
Practical approaches require shared responsibilities. National health systems and public payers must assess cost-effectiveness and budget impact through transparent health technology assessment processes like the National Institute for Health and Care Excellence in the United Kingdom, which systematically weighs clinical benefit against societal willingness to pay. Private insurers, particularly in fragmented systems, must negotiate coverage rules that consider long-term outcomes and portability of payment across insurers. Manufacturers have a duty to propose innovative financing such as annuities, risk-sharing agreements, or outcome-based contracts that spread cost or tie payment to real-world effectiveness. Independent bodies and courts sometimes arbitrate disputes when coverage is denied, but reliance on litigation undermines systematic priority setting.
Consequences of different decision-makers vary across territories and cultures. In high-income countries with centralized coverage, rigid rejection of high-cost cures can provoke public outcry and political backlash, while unregulated private markets can produce unequal access and catastrophic personal spending. Low- and middle-income countries face additional constraints: limited diagnostic infrastructure, workforce shortages for delivering gene therapies, and competing public health priorities that make universal access implausible without international financing or tiered pricing. Patient advocacy communities often shape policy by highlighting lived experience and mobilizing public sympathy; their voices can correct technocratic blind spots but also introduce pressure that may skew priority setting toward emotionally salient conditions.
A defensible governance model should be plural: independent assessment bodies to determine value, public payers to set coverage based on population priorities, manufacturers to accept innovative payment mechanisms, and patient representatives to ensure lived experience informs thresholds and exceptions. This distributed decision-making balances expertise, legitimacy, and compassion while aiming to sustain innovation and protect societal solidarity. Implementation will require transparent criteria, international cooperation on affordability, and mechanisms to address territorial inequities in diagnosis and care delivery.